Program
STSP-0902
A development code. Also written as “STSP-0902 ophthalmic solution” and “STSP-0902 injection”.
Its studies are mostly in Oligospermia · Keratitis · Asthenozoospermia, led by Staidson (Beijing) Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals | 53 open or running | phase 2since Apr 15, 2025 | Jul 2, 2024 | Sep 2027phase 2 · NCT07833943 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 2, 2024First study: phase 1 study in OligospermiaFirst studyNCT06563713 · 40 enrolled · China
- Sep 9, 2024Phase 1 study in Neurotrophic KeratitisNCT06597422 · 82 enrolled · China
- Apr 15, 2025Phase 2 study in Neurotrophic KeratitisNCT06975748 · 48 planned · China
- Apr 21, 2025Phase 1 study in OligospermiaNCT06948799 · 64 planned · China
- Sep 13, 2026Phase 2 study in Oligozoospermia and/or AsthenozoospermiaNCT07833943 · 72 planned · China
Ahead
- Sep 2027Primary completion: phase 2 study in Oligozoospermia and/or AsthenozoospermiaNCT07833943
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07833943Oligozoospermia and/or Asthenozoospermia · China | 2 | Not yet recruiting | Sep 2027 | 72 |
| NCT06948799Oligospermia · China | 1 | Recruiting | Jul 2026 | 64 |
| NCT06975748Neurotrophic Keratitis · China | 2 | Recruiting | Apr 2026 | 48 |
| NCT06597422Neurotrophic Keratitis · China | 1 | Completed | Jan 23, 2025 | 82 |
| NCT06563713Oligospermia · China | 1 | Completed | Feb 24, 2025 | 40 |
How it is read
Names in the registry
- “STSP-0902 ophthalmic solution”, 6 entries
- “STSP-0902 injection”, 3 entries
Codes read as this program: STSP0902.
Conditions, from the studies’ own filings
- Oligospermia, 2 studies
- Keratitis, 2 studies
- Asthenozoospermia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.